A Study of Influenza Virus Vaccines in Children and Adults
NCT00988143
Completed
The purpose of this study is to describe the immunogenicity of the prototype Quadrivalent Influenza Vaccine (QIV) compared with the 2009-2010 Trivalent Influenza Vaccine (TIV) and the 2008-2009 TIV among children and adults. Primary Objective: To describe the immunogenicity of the prototype Quadrivalent Influenza Vaccine (QIV) compared with the 2009-2010 Trivalent Influenza Vaccine (TIV) and the 2008-2009 TIV among adults. Observational Objectives: * To describe the safety of the 2009-2010 T... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
11/18/2013
Locations: Not set, Durham, North Carolina +3 locations
Conditions: Influenza
Register for Updates
Study of Quadrivalent Influenza Vaccine Among Adults
NCT01218646
Completed
The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain, and the investigational TIV containing the alternate B strain in adult subjects. Primary Objective: * To demonstrate non-inferiority of antibody responses to QIV compared with licensed 2010-2011 TIV (containing the primary B strain) and investigational TIV (containing the alternate B strain) as assessed by geometric mean... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2013
Locations: Not set, Hoover, Alabama +11 locations
Conditions: Influenza
Register for Updates
Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection
NCT00772343
Completed
Primary objective: To compare the event rate of CDI in groups assigned to ACAM-CDIFF™ vaccine versus placebo in the 9 week period after the third dose of the study vaccine in subjects with first episode of CDI receiving antibiotics standard of care. Secondary objective: To evaluate the safety of all dose groups of ACAM-CDIFF™ vaccine versus placebo in subjects with first episode of CDI receiving antibiotics standard of care.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
09/06/2013
Locations: Not set, Tampa, Florida +30 locations
Conditions: Diarrhea, Clostridium Difficile Infection
Register for Updates
Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
NCT01691339
Completed
The aim of this study is to evaluate the safety and immunogenicity of Fluzone vaccine (18 years to \<65 years of age and ≥ 65 years of age), Fluzone Intradermal vaccine (18 years to \<65 years of age), and Fluzone High-Dose vaccine (≥ 65 years of age). Primary Objective: * To describe the safety of the 2012 - 2013 formulation of Fluzone and Fluzone Intradermal vaccines in adults 18 to \< 65 years of age and the safety of the 2012 - 2013 formulation of Fluzone and Fluzone High-Dose vaccines in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2013
Locations: Not set, Boca Raton, Florida +3 locations
Conditions: Influenza
Register for Updates
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
NCT00006470
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +236 locations
Conditions: Lung Cancer
Register for Updates
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
NCT00002475
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor cells. Chemotherapy combined with vaccine therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide with tumor cell vaccine in treating patients who have metastatic cancer or cancer at high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2013
Locations: St. Vincent Medical Center - Los Angeles, Los Angeles, California
Conditions: Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Register for Updates
Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients
NCT00722098
Terminated
The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
07/05/2013
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Malignant Melanoma Stage IV
Register for Updates
Biological Therapy in Treating Patients With Prostate Cancer
NCT00002637
Completed
RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy using interleukin-2 and interferon gamma in treating patients with advanced prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/24/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Prostate Cancer
Register for Updates
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
NCT00019084
Completed
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for advanced cancer. PURPOSE: Phase II trial to study the effectiveness of a vaccine made with the patients' white blood cells mixed with tumor proteins in treating patients who have advanced cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2013
Locations: Medicine Branch, Bethesda, Maryland
Conditions: Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00019734
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with and without interleukin-2 in treating patients who have metastatic melanoma that has not responded to previous treatment.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/19/2013
Locations: Surgery Branch, Bethesda, Maryland
Conditions: Melanoma (Skin)
Register for Updates
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00054535
Completed
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have metastatic melanoma.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/18/2013
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland
Conditions: Melanoma (Skin)
Register for Updates
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00045227
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy with or without docetaxel in treating patients who have metastatic prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2013
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland
Conditions: Prostate Cancer
Register for Updates